| Document |
Document Title |
|
WO/2022/253341A1 |
Disclosed are 2, 8-diazaspiro [4.5] decane compounds, including (pyrido [3, 4-d] pyrimidin-4-yl) -2, 8-diazaspiro [4.5] decane compounds, (2, 6-naphthyridin-1-yl) -2, 8-diazaspiro [4.5] decane compounds, and (1, 7-naphthyridin-4-yl) -2, ...
|
|
WO/2022/256680A1 |
The disclosure provides compounds, or pharmaceutically acceptable salts thereof, and methods of using these compounds to inhibit Weel kinase and treat, for example, cancer in a subject. Claimed compounds include compounds (I).
|
|
WO/2022/253841A1 |
Compounds of the formula (I),are disclosed wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compo...
|
|
WO/2022/253328A1 |
An HPK1 kinase inhibitor, and a preparation method therefor and an application thereof. Specifically, a compound shown in formula (I), the compound having HPK1 inhibitory activity and being used for preparing a pharmaceutical composition...
|
|
WO/2022/253167A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for...
|
|
WO/2022/253101A1 |
The present invention relates to a pyridazinone compound as a PARP7 inhibitor, in particular to a compound as represented by the structure of formula I, which can be used as a PARP 7 inhibitor, and can be used for preparing drugs for tre...
|
|
WO/2022/251482A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2022/249992A1 |
Provided is a production method for a bipyridine derivative such that it is possible to obtain a high-purity target substance (including an intermediate) without purifying via column chromatography, said production method having a good y...
|
|
WO/2022/251497A1 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
|
|
WO/2022/250069A1 |
The present invention addresses the problem of providing a novel compound for controlling noxious organisms. This sulfur-containing pyrazole compound is a novel compound that can control noxious organisms. The sulfur-containing pyrazole ...
|
|
WO/2022/247757A1 |
Disclosed are a class of fluorine-substituted pyrimidopyridine compounds and the use thereof, and specifically disclosed are a compound as represented by formula (IV) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/216386A9 |
Disclosed herein is a method of reducing Miro1 level in a cell, the method comprising contacting the cell with an effective amount of a T-type calcium channel antagonist.
|
|
WO/2022/251588A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions and their use in protein degradation and treating disease, such as cancer. The heterobifunctional compounds feature thalidomide derived moieties that binds ...
|
|
WO/2022/247676A1 |
Disclosed in the present invention are a compound with a dipyrrolopyridine structure, and a preparation method therefor and the medical use thereof. The compound with the dipyrrolopyridine structure provided by the present invention has ...
|
|
WO/2022/247759A1 |
Disclosed in the present invention are an intermediate of a pyridone derivative and a preparation method therefor. The new intermediate compound of formula I, compound of formula E or compound of formula C of the present invention can be...
|
|
WO/2022/247760A1 |
Disclosed are compounds of formulae (I) and (II) or a pharmaceutically acceptable salt, a prodrug, a tautomer or a stereoisomer thereof and a solvate thereof; and a method for preparing the compounds of formulae (I) and (II), and a pharm...
|
|
WO/2022/247839A1 |
The present invention relates to the technical field of medicines, and in particular, to a PARP7 kinase inhibitor compound represented by general formula (I), a pharmaceutically acceptable salt or isomer thereof, a pharmaceutical composi...
|
|
WO/2022/247816A1 |
A nitrogen-containing heterocyclic compound, a preparation method therefor, and an application thereof in medicines. Specifically, the present disclosure relates to a nitrogen-containing heterocyclic compound as represented by general fo...
|
|
WO/2022/247743A1 |
Provided herein are a series of compounds and their use as an adjuvant. Provided herein are the compounds, a composition comprising the compounds, and the use thereof. These compounds can be used as an adjuvant for a vaccine, and compare...
|
|
WO/2022/250087A1 |
Provided is an organic scintillation material containing a polycyclic aromatic compound having four or more (hetero)aromatic rings, the polycyclic aromatic compound being at least one compound selected from the group consisting of fused ...
|
|
WO/2022/248885A2 |
This invention relates to compounds that may be useful for inhibiting RAS proteins. More specifically, this invention relates to compounds for inhibiting a broad spectrum of KRAS mutant proteins. The compounds of the invention may theref...
|
|
WO/2022/248883A1 |
The compounds of the invention are modulators of the Factor XII (e.g. Factor Xlla). In particular, the compounds are inhibitors of Factor Xlla and may be useful as anticoagulants.
|
|
WO/2022/246069A1 |
The present disclosure relates to a process for the preparation of Sotorasib and salts thereof useful as a pharmaceutical active compound. The present disclosure also relates to intermediates for the preparation of Sotorasib and salts th...
|
|
WO/2022/242753A1 |
The present disclosure relates to a pharmaceutically acceptable salt of a pyrazoloheteroaryl derivative and a crystal form thereof. In particular, the present disclosure relates to a pharmaceutically acceptable salt of a compound represe...
|
|
WO/2022/246059A1 |
The present disclosure is directed to the treatment of Alzheimer's disease by administering 1',3'-dihydro-2H-spiro[imidazo[1,2α]pyridine-3,2'-inden]-2-
one orally at a daily dose of 180mg as a single active agent or co-administered with...
|
|
WO/2022/243333A1 |
The present invention relates to N6-adenosine-methyltransferase inhibitors and to dual N6-adenosine-methyltransferase E3 ligase binders in cancer treatment.
|
|
WO/2022/241854A1 |
Embodiments of the present application disclose an electron transport material, a preparation method therefor, and an organic light-emitting diode, which relate to the technical field of display. The electron transport material has high ...
|
|
WO/2022/246177A1 |
Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a d...
|
|
WO/2022/242697A1 |
A compound represented by formula (I), or a tautomer, mesomer, racemate, enantiomer or diastereomer thereof or a pharmaceutically acceptable salt thereof, and a use thereof for preparing a drug for treating TYK2-mediated diseases.
|
|
WO/2022/242750A1 |
The present invention relates to a piperazine compound and a composition thereof, and the use thereof in the preparation of an antitumor drug.
|
|
WO/2022/245085A1 |
The present invention relates to a heteroaryl derivative and a use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR and/or HER2, and thus can be effectively used as a therape...
|
|
WO/2022/246179A1 |
Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a d...
|
|
WO/2022/242521A1 |
Disclosed in the present invention are a condensed azacyclic compound, the use thereof, and an organic electroluminescent device comprising the condensed azacyclic compound. The condensed azacyclic compound has a structure of a combinati...
|
|
WO/2022/242767A1 |
Provided in the present invention are a class of compounds as represented by formula (I), or a prodrug, a tautomer, a stereisomer, a solvate and an isotopic derivative thereof, or a pharmaceutically acceptable salt thereof. The compound ...
|
|
WO/2022/245776A1 |
Disclosed herein are compounds and methods for treating cancer. The compound has a formula according to Formula I: (I), or a pharmaceutically acceptable salt thereof. In some examples, the compounds are inhibitors of one or more cyclin-d...
|
|
WO/2022/245125A1 |
The present invention relates to: a crystalline form of a citric acid salt of a tricyclic derivative compound represented by chemical formula 1; a method for preparing the crystalline form of the citric acid salt; and a crystalline form ...
|
|
WO/2022/237875A1 |
A sulfoximine-containing ATR inhibitor compound as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the treatment of ATR-related or ATR-mediated diseases and/...
|
|
WO/2022/238347A1 |
The invention relates to novel compounds having the general formula Ib Ib wherein R1, R2, R3, R4, R5, and Z are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2022/238391A1 |
The invention relates to novel compounds of formula (I), wherein A1, A3, X, R1, R3, R4, R6, R7, R8 and n have the meanings indicated in the description, to the use thereof as acaricides and/or insecticides for controlling animal pests, a...
|
|
WO/2022/240213A1 |
The present invention relates to a novel benzothiazole derivative, a preparation method therefor, and a use thereof for preventing or treating liver diseases.
|
|
WO/2022/238500A1 |
The present invention relates to the synthesis of Poly (ADP ribose) polymerase (PARP) inhibitors and particularly to the radiosynthesis of PARP 1 inhibitors, more particularly to the synthesis of [18F] talazoparib.
|
|
WO/2022/237682A1 |
The present invention relates to a salt form of a pyrrolotriazine compound, a crystal form thereof, a preparation method therefor, and an application thereof, and in particular to an application in preparation of MNK1/2 inhibitor drugs a...
|
|
WO/2022/241265A1 |
The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing...
|
|
WO/2022/237889A1 |
A pharmaceutical composition. The pharmaceutical composition comprises N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyri
midin-2-yl)amino)-4-methoxy-2-(methyl(2-(methyl(methyl-d3)am
ino)ethyl)amino)phenyl)acetamide or a pharma...
|
|
WO/2022/237626A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for...
|
|
WO/2022/236407A1 |
New psilocybin and psilocin conjugates and their soluble salts with synergistic or additive therapeutic agents and stable formulations thereof, as well as their medical applications. The synergistic or additive conjugates may be used as ...
|
|
WO/2022/240277A1 |
The invention relates to novel compounds of formulae (I) and (II), to the use thereof as a drug, particularly for the treatment of SARS-CoV-2, for the treatment of COVID-19 disease and any diseases related to beta-coronaviruses, and for ...
|
|
WO/2022/241257A1 |
Disclosed are compounds, methods, compositions, uses, and kits that modulate (e.g., inhibit) nicotinamide phosphoribosyltransferase (NAMPT), the production of nicotinamide mononucleotide (NMN), the production of nicotinamide adenine dinu...
|
|
WO/2022/236578A1 |
The present disclosure provides certain quinazoline derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing...
|
|
WO/2022/237649A1 |
The present disclosure provides certain quinazoline derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment ofcancers mediatedby such proteins. Also provided are pharmaceutical compositions containing s...
|
